Pharmaceuticals

The pharmaceutical industry is a EUR 1 trillion sector and has been a major engine of economic growth and scientific advancement for decades. The industry encompasses a wide range of enterprises including large ethical drug multi-nationals (so-called Big Pharma), mid-sized specialty pharmaceutical companies, generic manufacturers, virtual pharmas, small biotechnology and biopharmaceutical firms, and all the various ancillary support and service companies that provide contract research, regulatory guidance, contract sales, and manufacturing technologies and raw materials.

Although growth has not been as robust in recent years—mainly due to price pressures, uncertainty in regulatory/reform measures, and weak drug pipelines— the demographic and structural drivers of demand in healthcare still exist: namely, the continued aging of the global population and the increasing sophistication and wealth of developing nations. Shifting epidemiology patterns and outbreaks, along with new challenges in chronic disease, cancer, heart disease, and degenerative disease will continue to impel the need for ever-better medicines. New understanding and technologies in drug delivery, and most especially in the fields of genomics, proteomics, and molecular biology generally, also hold promise for better therapeutics and a revival of profits.
Page 2/16
Category Tools

Generics in the Netherlands

August 2013 · MarketLine Generics in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2008-12, and forecast to 2017). € 259,00

OTC Pharmaceuticals in Germany

August 2013 · MarketLine OTC Pharmaceuticals in Germany industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). € 259,00

OTC Pharmaceuticals in the Netherlands

August 2013 · MarketLine OTC Pharmaceuticals in the Netherlands industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). € 259,00

OTC Pharmaceuticals in Mexico

August 2013 · MarketLine OTC Pharmaceuticals in Mexico industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). € 259,00

OTC Pharmaceuticals in Hungary

August 2013 · MarketLine OTC Pharmaceuticals in Hungary industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). € 259,00

Biotechnology in Belgium

August 2013 · MarketLine Biotechnology in Belgium industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). € 259,00

Biotechnology in Europe

August 2013 · MarketLine Biotechnology in Europe industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). € 259,00

OTC Pharmaceuticals in the Czech Republic

August 2013 · MarketLine OTC Pharmaceuticals in the Czech Republic industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). € 259,00

Biotechnology in Italy

August 2013 · MarketLine Biotechnology in Italy industry profile provides top-line qualitative and quantitative summary information including: market size (value 2008-12, and forecast to 2017). € 259,00

OTC Pharmaceuticals in Sweden

August 2013 · MarketLine OTC Pharmaceuticals in Sweden industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value and volume 2008-12, and forecast to 2017). € 259,00

Apotex, Inc. - SWOT, Strategy and Corporate Finance Report

July 2013 · MarketLine Apotex, Inc. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc. € 129,00

AAIPharma Services Corporation - SWOT, Strategy and Corporate Finance Report

July 2013 · MarketLine AAIPharma Services Corporation - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc. € 129,00

Sanofi - SWOT, Strategy and Corporate Finance Report

July 2013 · MarketLine Sanofi - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc. € 129,00

Chugai Pharmaceutical Co., Ltd. - SWOT, Strategy and Corporate Finance Report

July 2013 · MarketLine Chugai Pharmaceutical Co., Ltd. - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc. € 129,00

Abbott Laboratories - SWOT, Strategy and Corporate Finance Report

July 2013 · MarketLine Abbott Laboratories - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc. € 129,00

F. Hoffmann-La Roche Ltd - SWOT, Strategy and Corporate Finance Report

July 2013 · MarketLine F. Hoffmann-La Roche Ltd - SWOT, Strategy and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings, etc. € 129,00

IR Biosciences Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Terumo Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Derma Sciences, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Myriad RBM (formerly Rules-Based Medicine, Inc.) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Vivalis SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Siemens Healthcare - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Accentia Biopharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

InterMune, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Affitech A/S (formerly Pharmexa A/S) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Endo Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

PDL BioPharma, Inc. (formerly Protein Design Labs, Inc.) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

MediGene AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Strides Arcolab Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Merck & Co., Inc. (formerly Schering-Plough Corporation) - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Fresenius Kabi AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

TAKARA HOLDINGS, INC. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

BTG plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Novo Nordisk A/S - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Fresenius SE - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

GenVec, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Medivir AB - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Barr Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Horizon Pharma, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Immunomedics, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

GE Healthcare - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Ipsogen SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Bristol-Myers Squibb Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Charles River Laboratories International, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Illumina, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Aventis SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Novavax, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Barr Laboratories, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Acadia Healthcare Company, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00

Merrimack Pharmaceuticals, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

July 2013 · MarketLine Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. € 259,00
Options